Suspension of trading

Consensus Forte Biosciences

Stocks

FBRX

US34962G2084

Market Closed - Nasdaq 21:00:00 26/08/2026 BST			5-day change	1st Jan Change
76.99 ^USD	+0.03%		+0.09%	+182.32%

08-27	Argenx SE completed the acquisition of Forte Biosciences, Inc..	CI
08-27	Argenx Completes Acquisition of Forte Biosciences	MT

Evolution of the Average Target: Forte Biosciences

Evolution of the Target Price: Forte Biosciences

Changes in Analyst Recommendations: Forte Biosciences

347.wqoDsjlKz9lJqC38-70fIJdeH3BeDTAtgJjCcB-aNvI.jtxihAoLt-wN72LLlMV9VOEfaBpvVVFf1821RE3XAJWT_G7BTDCmkXj8dA~878ff20faa758b3c14012e43dee47576

Analysts' recommendations: Forte Biosciences

07-27	Global markets live: Nvidia, Coca-Cola, Rocket Lab, KKR, OpenAI…
07-21	Barclays Initiates Forte Biosciences at Overweight With $74 Price Target	MT
07-09	Top Midday Gainers	MT
03/10/25	Forte Biosciences reports inducement grants under Nasdaq listing rules	RE
18/08/25	Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target	MT
02/04/25	Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating	MT
21/01/25	TD Cowen Initiates Forte Biosciences at Buy	MT
15/11/24	Chardan Boosts Price Target on Forte Biosciences to $64 From $3, Keeps Buy Rating	MT
30/05/24	Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target	MT
20/09/21	Forte Biosciences : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4	MT
07/09/21	Forte Biosciences : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy	MT
07/09/21	Forte Biosciences : Brookline Capital Downgrades Forte Biosciences to Hold from Buy	MT
03/09/21	Forte Biosciences : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket	MT
03/09/21	Forte Biosciences : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy	MT
03/09/21	Forte Biosciences : B. Riley Downgrades Forte Biosciences to Neutral from Buy After Lead Program FB-401 Failed to Strike Primary Endpoint, Lowers PT to $3 from $73	MT
03/09/21	Forte Biosciences : Truist Securities Downgrades Forte Biosciences to Hold from Buy	MT
14/05/21	Forte Biosciences : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis	MT
26/03/21	Forte Biosciences : Citigroup Starts Forte Biosciences at Buy With $75 Price Target	MT
17/03/21	Forte Biosciences : Chardan Capital Adjusts Price Target on Forte Biosciences to $105 From $115, Maintains Buy Rating	MT
11/11/20	Forte Biosciences : Chardan Adjusts Forte Biosciences' Price Target to $115 From $110, Keeps at Buy	MT
25/08/20	Forte Biosciences : Shares Higher After Truist Initiates Coverage	DJ